Once-Weekly Somatrogon Reduces Treatment Burden in Children With GHD
The C0311002 study compared the patient perception of treatment burden with use of somatrogon to somatropin in 87 children aged 3 to 17 years with GHD.
The C0311002 study compared the patient perception of treatment burden with use of somatrogon to somatropin in 87 children aged 3 to 17 years with GHD.
Sogroya is administered by subcutaneous injection one time each week.
Mycapssa is an oral somatostatin analogue.
One nonfatal adverse event has been reported during the timeframe the affected product was distributed.
The FDA has approved Mycapssa® (octreotide; Chiasma) capsules for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
Recordati Rare Diseases, Inc. announced the availability of Isturisa® (osilodrostat) tablets for the treatment of adults with Cushing disease for whom pituitary surgery is not an option or has not been curative. Isturisa is a cortisol synthesis inhibitor that works by blocking the enzyme 11-beta-hydroxylase, which is responsible for the final step of cortisol biosynthesis…
The FDA has approved Fensolvi (leuprolide acetate; Tolmar Pharmaceuticals) for the treatment of pediatric patients 2 years of age and older with central precocious puberty.
The FDA has granted Orphan Drug designation to TransCon hGH (lonapegsomatropin; Ascendis Pharma), a long-acting prodrug of somatropin, for the treatment for growth hormone deficiency.
This week we talk about the latest COVID-19 news; New approvals for chronic fibrosing interstitial lung disease and Cushing disease; and stronger safety warnings for montelukast.
The Food and Drug Administration (FDA) has approved Isturisa® (osilodrostat; Recordati) for the treatment of adults with Cushing disease for whom pituitary surgery is not an option or has not been curative.